

Supplementary Information

A New Approach to Reduce Toxicities and to Improve Bioavailabilities of Platinum-Containing Anti-Cancer Nanodrugs

Li Liu^{1†}, Qing Ye^{1†}, Maggie Lu², Ya-Chin Lo², Yuan-Hung Hsu², Ming-Cheng Wei², Yu-Hsiang Chen³, Shen-Chuan Lo³, Shian-Jy Wang³, Daniel J. Bain⁴, Chien Ho^{1*}

¹ Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA; ² Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan; ³ Material and Chemical Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan; ⁴ Department of Geology and Planetary Science, University of Pittsburgh, Pittsburgh, PA.

[†]LL and QY contributed equally.

* Correspondence author at: Chien Ho, Department of Biological Sciences, Carnegie Mellon University, 4400 Fifth Ave, Pittsburgh, PA 15213, USA; Tel: +1 412 268 3395; Fax: +1 412 268 7083; E-mail address: chienho@andrew.cmu.edu

Figures




Fig S1. Dynamic light scattering (DLS) analysis of the hydrodynamic diameter of DACHPt/HANP.




Fig S2. Cryo transmission electron microscope (Cryo-TEM) image of DACHPt/HANP.




Fig S3. Changes in the bioavailability of DACHPt/HANP nanodrug [calculated by the area under the curve (AUC), by the trapezoidal rule, using KaleidaGraph 4.1 (Synergy Software, Reading, PA)] upon Intralipid pre-treatment: (A) 5 hr; (B) 24 hr; (C) 72 hr after the nanodrug administration. * $p < 0.0001$; ** $p < 0.001$; # $p > 0.05$.